Dr. MacLeod joined ADARx in January 2023 as our Chief Scientific Officer having gained extensive experience in the oligonucleotide field throughout his career. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, most recently as Vice President and Franchise Head of Oncology. Dr. MacLeod has led the strategic and scientific efforts of several multidisciplinary drug discovery teams in the discovery and clinical development of 15 novel investigational therapeutics and over 100 high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada, and his Ph.D. in Cancer Epigenetics from McGill University.
